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Abstract
Background: The worldwide expanding Mycobacterium tuberculosis W-Beijing family is associated
with treatment failure and relapse. Its identification currently relies on spoligotyping and
conventional sequencing. We developed pyrosequencing as an alternative method for its
identification.
Findings: Pyrosequencing found a G/A substitution in the Rv0927c-pstS3 intergenic spacer and a
RD105 deletion, identifying 8/104 M. tuberculosis isolates as W-Beijing isolates. In addition,
pyrosequencing found a previously unreported TGC deletion in the Rv0927c gene of W-Beijing
isolates. Total concordance was found between the pyrosequencing data and conventional
sequencing, as well as reference molecular identification. Multispacer Sequence Typing assigned the
W-Beijing isolates to the Asian lineage and the 96 non-W-Beijing isolates to the Euro-American
lineage (P < 10-5). The W-Beijing isolates were all susceptible to streptomycin, rifampin, isoniazid,
ethambutol, and pyrazinamide; no resistance-associated mutations were detected in these eight W-
Beijing isolates. There were no statistically significant differences in the antibiotic susceptibility of
W-Beijing and non-W-Beijing isolates (p = 0.2, X2 test). Pyrosequencing correctly identified M.
tuberculosis organisms in 26/26 sputum specimens exhibiting acid-fast bacilli. Pyrosequencing results
were obtained within four hours, incurring an estimated cost of 1.86 €/test.
Conclusion: Pyrosequencing of the Rv0927c gene and adjacent intergenic spacer is an efficient,
low-cost technique for the rapid identification of W-Beijing isolates.
Background
Tuberculosis is the leading cause of death due to a single
infectious agent in adults, killing about three million peo-
ple every year [1]. One-third of the human population is
thought to be infected by Mycobacterium tuberculosis, the
main bacterial agent of human tuberculosis [2]. DNA fin-
gerprinting analyses discriminated several M. tuberculosis
lineages [3,4], including the W-Beijing family initially
found among Chinese isolates [5]. W-Beijing isolates were
subsequently shown to be highly prevalent throughout
Asia and to have spread to other continents and countries,
including the USA and South Africa [6], exhibiting a prev-
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alence as high as 62% in some geographic areas [7]. In
addition to their worldwide diffusion, W-Beijing isolates
induce a more severe pathology than other M. tuberculosis
genotypes by eliciting a reduced level of cytokine and a
lack of associated Th1-type immunity [8]. W-Beijing
organisms have been also been linked to drug resistance,
treatment failure and relapse [9,10].
These data emphasize the importance of rapid identifica-
tion of W-Beijing isolates for epidemiology and infection
control. W-Beijing isolates can be identified by spoligo-
typing, which reveals the absence of spacers 1-34 and the
specific A1 insertion of an IS 6110 element in the origin of
replication [5]. Genomic microarray approaches revealed
several large sequence polymorphisms which classified
W-Beijing isolates into five subtypes [4,11]. In particular,
RD105 was found to be specific to W-Beijing isolates [11].
Reverse genetics demonstrated one deletion in the
Rv0927c gene and a single nucleotide polymorphism
(SNP) in the Rv0927c-pstS3 intergenic spacer, both of
which are specific to W-Beijing organisms [12]. However,
time and cost as well as technical demand of these meth-
ods still limit their wide application in laboratories.
Efforts towards the development of more rapid and
affordable methods yielded the development of polymer-
ase chain reaction-single-strand conformational polymor-
phism (PCR-SSCP) analysis [13].
Pyrosequencing technology is a sequencing method that
is mostly used for short-read sequencing and SNP analy-
ses. It has been used for the identification of various bac-
teria including mycobacteria [14], as well as for the
detection of drug-resistance in M. tuberculosis [15-17].
In the present study, we developed an Rv0927c gene and
adjacent intergenic spacer pyrosequencing method for the
rapid identification of W-Beijing isolates, and applied this
method to identify W-Beijing isolates among M. tuberculo-
sis isolates made in our laboratory over two years.
Findings
Methods
Bacterial strains
A collection of 104 M. tuberculosis isolates cultured from
respiratory tract specimens as part of the routine activity in
our laboratory in 2005-2006 were identified by conven-
tional methods [18]. For each isolate, one colony grown
on 5% sheep blood agar (Biotechnology Appliquée,
Dinan, France) was removed using a sterile loop, and
mixed with freezing beads for storage at -20°C prior to
inactivation and DNA extraction with a Qiagen kit (Qia-
gen, Courtaboeuf, France). This study has been approved
by the Ethics Committee, Marseilles.
Conventional DNA sequencing, reference molecular identification, 
and Multispacer Sequence Typing (MS) genotyping
The Rv0927c gene and Rv0927c-pstS3 intergenic region
were PCR amplified as previously described in the pres-
ence of negative controls consisting of PCR mix without
DNA [12]. PCR products were sequenced by Sanger
sequencing using the BigDye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems, Courtaboeuf,
France). Sequencing electrophoresis was performed with a
3100 genetic analyzer (Applied Biosystems) in both direc-
tions. The sequences were edited using the Auto assembler
program (Applied Biosystems) and aligned using CLUS-
TAL W http://bioinfo.hku.hk/services/analyseq/cgi-bin/
clustalw_in.pl and NPS Multalin multiple alignment
http://npsa-pbil.ibcp.fr. M. tuberculosis isolates identified
as belonging to the W-Beijing family were confirmed by
parallel detection of the RD105 deletion as previously
described [4]. M. tuberculosis isolates were also genotyped
using MST to assess their phylogeographical lineage, as
previously described [19].
Pyrosequencing
Based on polymorphisms identified using the above men-
tioned conventional DNA sequencing as previously
described [12], the pyrosequencing primers used in this
procedure were designed using the PSQ assay design
(Biotage, Uppsala, Sweden) (Table 1). The Rv0927c inter-
genic region was amplified using Rv0927c-pstS3F. biotin
and Rv0927c-pstS3R; PCRs were performed at a final vol-
ume of 50 μL containing 33 μL of H2O, 5 μL of 10× buffer
(Qiagen), 2 μL of 25× MgCl2, 5 μL of 10× dDNTP, 1 μL of
forward primer (10 pmol/μL), 1 μL of reverse primer (10
pmol/μL), 0.25 μL of Hotstart Taq (Qiagen), and 2 μL of
target DNA. Appropriate negative controls consisting of
PCR mix without target DNA were also included for each
M. tuberculosis isolate. PCRs were performed according to
the following program: enzyme activation at 95°C for 15
min, followed by 34 cycles comprising 95°C for 30 s,
60°C for 30 s, 72°C for 1 min, and a 5-min final elonga-
tion step at 72°C. The Rv0927c gene was amplified in par-
allel using Rv0927c F. biotin and Rv0927c R (Table 1), as
described above. The expected 70-bp product was ana-
lyzed in a 2% agarose gel. Fifty microliters of binding
buffer (Pyrosequencing AB, Uppsala, Sweden) and 5 μL of
Table 1: Primers used for amplification and pyrosequencing 
analysis of Rv0927c in M. tuberculosis isolates.
Primer name Sequence (5'-3')
RV0927c-pstS3F. biotin Biotin-TTGACCCCTGATGATGGAC
RV0927c-pstS3R ACGGCATACGGACATCCTT
RV0927c-pstS3Seq ACATCCTTCCCCTGA
RV0927c F CCGGAGTGTTCCAGCATCA
RV0927c R. biotin Biotin-GGACGCCTTCGCCTTCAA
RV0927c Seq CACCGCCGCGACGGTCBMC Research Notes 2009, 2:239 http://www.biomedcentral.com/1756-0500/2/239
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streptavidin-coated Sepharose beads were added to 50 μL
of PCR product, and the solution was vigorously mixed
for 10 min. The biotinylated PCR products were immobi-
lized on streptavidin-coated Sepharose beads and sepa-
rated from the nonbiotinylated strand by denaturation in
200 μL of denaturation buffer (Pyrosequencing AB) for 5
s, followed successively by vacuum filtration in 200 μL of
ethanol, 200 μL of washing water, and 200 μL of sterile
water. The templates were then transferred to a 96-well
plate containing 43.5 μL of annealing solution and 1.5 μL
of sequencing primer. The annealing reaction was per-
formed at 83°C for 2 min on a thermoblock (Applied Bio-
systems). Pyrosequencing was performed with an
automated PSQ™ 96 system (Pyrosequencing AB). The
four different deoxynucleotide triphosphates were added,
with cyclic dispensation of the enzymes and substrates
(Pyrosequencing AB). The pyrosequencing data were eval-
uated using Peak Height Determination Software v1.1
(Pyrosequencing AB), and 96 reactions were completed in
11 min.
Antibiotic resistance analysis
The susceptibility to streptomycin, rifampin, isoniazid,
ethambutol and pyrazinamide was tested according to
standard methods [18]. Rifampin, isoniazid, and etham-
butol-resistance were screened among M. tuberculosis iso-
lates based on characterization of resistance-associated
hot mutations, as previously described by pyrosequencing
[15].
Statistical analyses
A correlation between M. tuberculosis isolates identified as
belonging to the W-Beijing family and their assignment
into a phylogeographical lineage defined by MST was
tested using the Chi Square test (Epi Info version 3.4.1,
Centers for Disease Control and Prevention, Atlanta,
USA). We also evaluated differential susceptibility to anti-
biotics between W-Beijing and non-W-Beijing isolates.
Clinical specimens
We selected 26 respiratory tract specimens, which were
positive by Ziehl-Neelsen staining, and cultured the iden-
tified M. tuberculosis using conventional methods [18].
Pyrosequencing was performed directly on inactivated
clinical specimens. Eight negative controls consisted of
respiratory tract specimens that were negative for Ziehl-
Neelsen staining, and these controls remained negative in
culture
Results and Discussion
Rapid expansion of the M. tuberculosis W-Beijing family in
various parts of the world urged the development of
molecular tools for its rapid detection in the clinical labo-
ratory. Current methods rely on PCR pattern analysis, but
lack sequencing confirmation for the RD105 deletion
method and PCR-SSCP method [13] or rely on conven-
tional Sanger sequencing, a one-day long procedure that
delays detection [11]. In the present study, we took advan-
tage of the ease of pyrosequencing technology to develop
a method for the rapid detection of W-Beijing isolates.
In all PCR experiments, negative controls remained nega-
tive and M. tuberculosis isolates yielded an Rv0927c-pstS3
intergenic spacer amplicon of the expected size (270 bp)
and Rv0927c gene fragment of 790 bp. Pyrosequencing
patterns were clear and accurate, and the sequences
obtained for codon 127 in the Rv0927c-pstS3 intergenic
spacer, as well as a new deletion at codon 115 in the
Rv0927c gene, could be read directly from the pyrose-
quencing spacer (figure 1). Eight of 104 isolates yielded
the G/A substitution in the Rv0927c-pstS3 intergenic
region, in contrast to the remaining 96 isolates (figure 1).
The RD105 deletion was also detected in the same eight
isolates (PCR product size, 761 bp instead of 1,466 bp in
the remaining 96 isolates). These features identified the 8
isolates as W-Beijing isolates as confirmed by reference
methods. Pyrosequencing assignment agreed with con-
ventional DNA sequencing and reference molecular
assignment for 104/104 (100%) M. tuberculosis isolates.
In the Rv0927c gene, pyrosequencing clearly identified a
new TGC deletion in the eight W-Beijing isolates instead
of the AGC deletion previously described [12]. We verified
the absence of this new TGC deletion in complete genome
sequences of M. tuberculosis, and BLAST analysis against
the Rv0927c gene sequence indicated that this TGC dele-
tion was original (figure 1). The Rv0927c gene sequence
in the other 96 M. tuberculosis isolates showed complete
identity with the reference non-W-Beijing M. tuberculosis
H37Rv strain (Genbank: AL123456). This deleted
sequence could still be translated in silico. MST identified
the ST3 profile in 8/8 W-Beijing isolates, assigning them
to the Asian lineage [19] (P < 10-5). The remaining 96/104
M. tuberculosis were distributed into 10 ST profiles and
assigned to the Euro-American lineage (Table 2).
The fact that pyrosequencing found a previously unre-
ported deletion in W-Beijing isolates illustrates the advan-
tage of sequencing over non-sequencing-based methods
of identification. Sequencing-based methods allow for the
discovery of new genotypes within bacterial species, while
latter methods could miss such variants and could yield
inaccurate identification data. While sequencing is of
interest for accurate identification of M. tuberculosis iso-
lates, conventional Sangers'method is a time and
resources-consuming method. In the present study, pyro-
sequencing was performed within five hours, including a
four-hour PCR. The cost of a pyrosequencing reaction is
~1.86 €, less than our conventional DNA sequencing reac-
tion, which is ~2.64 €. The objectivity of this technique isBMC Research Notes 2009, 2:239 http://www.biomedcentral.com/1756-0500/2/239
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extremely useful for medical microbiology applications,
as the skilled interpretation of bands required for RFLP
[20] is not necessary. Finally, the ability to perform the
pyrosequencing assay using inactivated clinical samples
has been demonstrated previously [21] and provides a
considerable advantage; for example, this high-through-
put assay can prevent multi-drug resistant episodes via
rapid screening of the W-Beijing isolates. In this study,
PCR products were generated from all 26 respiratory tract,
acid fast bacilli-positive clinical specimens, and negative
controls remained negative. Pyrosequencing identified no
polymorphisms in the Rv0927c-pstS3 intergenic spacer or
Rv0927c gene, thereby identifying these organisms as
non-W-Beijing; MST further assigned them to the Euro-
American lineage [19].
The 7.7% prevalence of W-Beijing isolates we found in a
large cosmopolitan area of Southern France is higher than
that reported in other French areas [22] and in Western
Europe [23]. The antibiotic susceptibility pattern of the
104 M. tuberculosis isolates was assessed by molecular and
conventional methods. The eight W-Beijing isolates char-
acterized herein were susceptible to 5/5 antibiotics tested,
unlike those reported in other studies [24]. No statistically
significant differences were observed regarding in vitro
susceptibility between eight W-Beijing and 96 non-W-Bei-
jing isolates (p = 0.2, X2 test). Molecular analyses revealed
no mutations associated with drug resistance in the eight
W-Beijing isolates. However, there is no constant associa-
tion between a W-Beijing family and drug resistance [25].
Pyrosequencing chromatograph of the wild type Rv0927c-pstS3 intergenic region (A), the W-Beijing type Rv0927c-pstS3 inter- genic region (B), the wild type Rv0927c gene (C), and the W-Beijing type Rv0927c gene (D) Figure 1
Pyrosequencing chromatograph of the wild type Rv0927c-pstS3 intergenic region (A), the W-Beijing type 
Rv0927c-pstS3 intergenic region (B), the wild type Rv0927c gene (C), and the W-Beijing type Rv0927c gene 
(D).
Table 2: Assignment of M. tuberculosis to a geographic lineage by 
MST.
Geographic lineage MST profile Number of isolates
Asian lineage ST3 8
Euro-American lineage ST8 29
ST19 17
ST17 13
ST23 10
ST6 8
ST28 7
ST14 5
ST21 3
ST8 2
ST4 2BMC Research Notes 2009, 2:239 http://www.biomedcentral.com/1756-0500/2/239
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For example, the acquisition rate for rpoB  gene point
mutations conferring rifampin resistance is similar in W-
Beijing and non-W-Beijing isolates [26].
Conclusion
In conclusion, we developed a pyrosequencing-based
method for rapid, clear, and accurate detection of W-Bei-
jing  M. tuberculosis isolates and respiratory tract speci-
mens. In this study, W-Beijing isolates comprised 7.7% of
M. tuberculosis and belonged to the East Asian lineage. The
low-cost assay described herein could be used to comple-
ment current routinely used techniques, and could replace
the time-consuming molecular tests presently used to
identify W-Beijing isolates.
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